Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma

@article{Donskov2005TwoRP,
  title={Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma},
  author={Frede N. Donskov and Mark R. Middleton and Kirsten Fode and Peter Meldgaard and Wasat Mansoor and Jeremy Lawrance and Nicholas Thatcher and Hanne Marie Nellemann and Hans von der Maase},
  journal={British Journal of Cancer},
  year={2005},
  volume={93},
  pages={757 - 762}
}
Histamine inhibits formation and release of phagocyte-derived reactive oxygen species, and thereby protects natural killer and T cells against oxidative damage. Thus, the addition of histamine may potentially improve the efficacy of interleukin-2 (IL-2). Two randomised phase II trials of IL-2 with or without histamine dihydrochloride (HDC) in patients with metastatic renal cell carcinoma (mRCC) were run in parallel. A total of 41 patients were included in Manchester, UK and 63 in Aarhus… CONTINUE READING
12 Citations
38 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Similar Papers

Loading similar papers…